Checked.be · Company dossierhttps://checked.be/en/c/2pharma-0886662746 · as of 21-11-2026
2PHARMA
ActivePublic limited company · founded 2007 · active for 19 yearsKortrijksesteenweg 1091, 9051 GhentKBO/BCE: BE 0886.662.746subsidiary of Name hiddenVisible after signing in
Save to list
With a free account you keep companies in your own lists to find and compare them later.
100%Name hiddenVisible after signing in and 1 other
Documentsfilings and deeds
09-07-202622 days before the deadline
2025abbreviated format
Gross margin from -€251 to €296,218Result from €83,988 to €120,628Equity from €658,838 to €779,467Debts from €264,421 to €343,314Cash from €3,310 to €756
2 directors joined, the latest on 29-04-2026. 3 are in office now.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 17,817 companies had the same profile as 2PHARMA has now. Each dot stands for 45 companies, two years later.
96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
Small
10 to 20 years old
solvency 30% or more
a profit of 5% of the balance sheet or more
Test of the method
The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,817 companies, not a prediction for 2PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Signal visible after signing inVisible after signing in
Signal hidden, visible after signing inVisible after signing in
Hidden signalVisible after signing in
Signal visible after signing inVisible after signing in
Signal hidden, visible after signing inVisible after signing in
Board and ownership
Hidden nameVisible after signing in
Managing director, Name after signing inVisible after signing in
Name hiddenVisible after signing in
Director, Hidden nameVisible after signing in, since 30-03-2026
Name after signing inVisible after signing in
Director, Name hiddenVisible after signing in
Hidden nameVisible after signing in 100%score XXVisible after signing inequity €34,480 (2025) · annual accounts 2025 of Name hiddenVisible after signing in
2 directors appointed, 3 resignations, 3 reappointmentsName after signing inVisible after signing in (managing director), Name hiddenVisible after signing in and Hidden nameVisible after signing in reappointed · Name after signing inVisible after signing in, Name hiddenVisible after signing in and Hidden nameVisible after signing in resign · Name after signing inVisible after signing in and Name hiddenVisible after signing in appointed · General meeting of 30-03-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0886662746
Registered office moved from Merelbeke to Sint-Denijs-Westrem
The registered office moved from Lembergsesteenweg 25a, 9820 Merelbeke to Kortrijksesteenweg 1091 bus B, 9051 Sint-Denijs-Westrem · Board meeting of 25-01-2022 · Gazette deed
Registered office moved from Genk to Merelbeke
The registered office moved from Woudstraat 3, bus B, 3600 Genk to Lembergsesteenweg 25A, 9820 Merelbeke · Hidden nameVisible after signing in acts as permanent representative · Board meeting of 17-05-2019 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as 2PHARMA: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €879,000 and €1.9m, founded between 2002 and 2009.
2PHARMA has been active since 2007 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €779,467 and a net result of €120,628.
Equity has been growing by about 16% per year since 2018. Its solvency ranks better than 76% of 10,802 sector peers (NACE 46) in financial year 2025.
According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of 2PHARMA?
2PHARMA is a public limited company (NV).
When was 2PHARMA founded?
2PHARMA was founded on 19-01-2007.
Is 2PHARMA still active?
Yes, 2PHARMA is an active enterprise in the KBO register.
How many employees does 2PHARMA have?
2PHARMA had an average of 2.3 full-time equivalents in financial year 2019, according to the filed annual accounts.Financials
What is the turnover of 2PHARMA?
The turnover in financial year 2025 is about €1.4m. This figure is estimated from the gross margin of €296,218 and 36 comparable companies (NACE 464). It probably lies between €1.1m and €2.1m. In financial year 2024 turnover was €1.3m.
Is 2PHARMA profitable?
In financial year 2025, 2PHARMA made a profit of €120,628.
Where can I find the annual accounts of 2PHARMA?
2PHARMA filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of 2PHARMA due?
2PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline